have the ability to enter transmissible plasraids or chromosomes (4) . Resistance can be transferred horizontally by plasmids or by chromosomally located conjugative transposons that spread the resistance to other species. It has been postulated that Escherichia colt transferred the ability to produce [5-1actamase enzymes that destroy compounds with a lS-lactam nucleus ( Fig. 2 
) into
Haenu3philus influenzae by initially infecting Haeruophilus parainfluenzae (5) . Intergenus spread of resistance can occur between Gram-positive species such as staphylococci and enterococci and between Enterobacteriaceae and Pseudonumas or anaerobes such as Bacteroides (6) . Gram-positive species can transfer resistance to Gram-negative species, but the reverse is uncommon.
Antimicrobial agents are rendered inactive by three major mechanisms: (i) inactivation of the antibiotic by destruction or modification, (it) prevention of access to the target, and (iii) alteration of the antibiotic target site (3) . Some examples of inactivation are 13-1actamase and aminoglycosideinactivating enzymes (7, 8) (Table 2 ). The alteration of permeability or efllux of an agent occurs for [8-1actams, aminoglycosides, and tetracyclines (9) , and a single amino acid change in an enzyme alters the sensitivity of the targets for [8-1actams, macrolides, and fotate synthesis antagonists (3, lO, 1 I) .
The stunning success of the pharmaceutical industry in the United States, Japan, the United Kingdom, France, and Germany in creating new antibiotics over the past three decades has caused society and the scientific community to become complacent about the potential of bacterial resistance. There are countless antibiotics: more than 50 penicillins, 70 cephalosporins, 12 tetracyclines, 8 aminoglycosides, 1 monobactam, 3 carbapenems, 9 macrolides, 2 new streptogramins, and 3 dihydrofolate reductase inhibitors (1) . Despite all these antibiotics, a person could die in a hospital in New York, San Francisco, Paris, Barcelona, Tokyo, or Singapore as a result of a resistant bacterial infection.
Antibiotics are available that effectively inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication ( Fig. 1 and Table 1 ). Bacteria can resist antibiotics as a result of chromosomal mutation or inductive expression of a latent chromosomal gene or by exchange of genetic material through transformation (the exchange of DNA), transduction (bacteriophage), or conjugation by plasmids (extrachromosomal DNA) (2) . Conjugation with plasmid transfer of DNA is particularly common among the The author is professor of Medicine and Pharmacology at the College of Physicians & Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032.
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Enterobacteriaceae, Pseudomonas, and anaerobic species (2, 3) . In addition to conjugative plasmids, bacteria may possess transposons, the so-called jumping genes, that
Staphylococci
In 1941, virtually all strains of Staphylococcus ameus worldwide were susceptible to penicillin G, but by 1944 S. aureus was capable of destroying penicillin by means of penicillinase, which today is called a . Today, in excess of 95% of S. aureus worldwide is resistant to penicillin, ampicillin, and the antipseudomonas penicillins (12) .
The pharmaceutical industry responded to this challenge with the synthesis of methicillin, a semisynthetic penicillin. Resistance to methicillin was noted in hospitals in the United Kingdom, Poland, and Denmark, but such resistance was rare in the United States until the 1980s when methicillin-resistant S. aureus (MRSA) became a problem, particularly in long-term care facilities and among narcotics abusers (12, 13) .
MRSA is resistant to all 13-1actams, penicillins, cephalosporins, carbapenems, and penems ( Fig. 2) because of a mecA gene that produces a new penicillin binding protein (PBP) 2a that has a low affinity for 13-1actam antibiotics (12, 14) . PBPs are transpeptidases that cross-link the cell wall of bacteria. They are called PBPs because radiolabeled penicillin binds to these proteins and is used as a marker to which the [3-1actam compounds bind, thus inhibiting cell wall synthesis.
In burn centers, there is a ninefold increase in the chance of acquiring or developing a methicillin-resistant strain if the patient is treated with a 13-1actam agent, and 14% of burn patients who become colonized with MRSA will develop bacteremia (15) . In long-term care facilities, patients and staff carry these organisms in their nares or on their hands, and approximately 15% of patients will become infected per 100 days once they are colonized with MRSA (13) . Approximately 25% of patients who carry MRSA will have an episode of infection, compared to 4% of those who are colonized with susceptible S. aureus (16) . As a result of transposition and site-specific integration in many MRSA, the chromosome mediates resistance not only to 13-1actam antibiotics but to other antibiotics such as erythromycin, fusidic acid, tetracycline, minocycline, streptomycin, spectinomycin, and sulfonamides and to disinfectants and toxic metals such as cadmium and mercury (12, 17) . Resistance to these compounds is a result of different mechanisms. Tetracyclines undergo efflux thai is a result of synthesis of a protein that removes the antibiotic. Aminoglycosides are modified through acetylation, adenylation, or phosphorylation and do not bind to ribosomes, and toxic metals are converted to other forms and excluded from the interior of the bacteria. The emergence of MRSA as a major problem worldwide has resulted in an increased use of vancomycin, the only agent that effectively treats these bacteria, but this increased use of vancomycin has created vancomycin resistance in other species such as enterococci.
MRSA is a classic example of the downfall of a new antimicrobial agent with respect to one species. In the mid1980s, the new fluoroquinolone antimicrobial agents, such as ciprofloxacin, inhibited MRSA at <2 I.tg/ml (18) . Fluoroquinolones eradicated the nasal carrier state of MRSA and cured serious infection that was a result of MRSA (18) . It was assumed that the problem of MRSA was rapidly drawing to a conclusion. This was far from the case. Today at the ColumbiaPresbyterian Medical Center in New York City, less than 20% of MRSA is inhibited by any of the commercially available fluoroquinolone antibiotics. A study by the Centers for Disease Control showed that ciprofloxacin resistance of MRSA went fiom less than 5% to greater than 80% within 1 year, and in the Veterans Administration Hospital in Portland, Oregon, the MRSA that colonized in elderly men hospitalized there were all resistant to ciprofloxacin (19) . Fluoroquinolone-resistant MRSA is present in the United Kingdom, Europe, Japan, and other parts of the world. Fluoroquinoione resistance of MRSA is a result of an altered codon 84 or codon 85 in DNA gyrase and hence an alteration of the target (20) .
Mupirocin, a pseudomonic acid derivative that interferes with protein biosynthesis, is highly effective against MRSA (l). Application ofmupirocin to the nares results in eradication of the nasal carriage of S.
aureus. This is extremely important because the nares are the site where MRSA and susceptible staphylococci persist. Hands are colonized with staphylococci, and unfortunately because most individuals touch their noses many times each day, the organisms are spread from hospital workers to patients and from patient to patient. Mupirocin has been available as a topical agent for only a short time in the United States. However, in the United Kingdom where the agent has been available for a number of years, MRSA with plasmid resistance to mupirocin has been found (21) . These aspects about staphylococcal resistance illustrate the rapid ability of bacteria to become resistant to virtually all antibacterial agents, whether of natural origin, such as penicillin G or aminoglycosides, partially synthetic (cephalosporins), or totally synthetic, such as fluoroquinolones.
Staphylococci have acquired resistance to aminoglycosides because of aminoglycoside-modifying enzymes (12) . Aminoglycosides can be phosphorylated, adenylated, or acetylated (Fig. 4) . This changes the threedimensional configuration of the compounds so that they do not bind adequately to the receptor proteins on the ribosomes SCIENCE * VOL. 257 ° 21 AUGUST 1992 (22, 23) .
Although rifampin, which inhibits DNAdirected RNA polymetase activity, inhibits many S. epidermidis, resistance routinely develops when rifampin is used singly because most populations of staphylococci contain bacteria that have one of the four subunits of the enzyme with low affinity for rifampin, and even when rifampin is combined with vancomycin to achieve synergy, resistance to rifampin develops. S. saprophyticus, a cause of 10% of uncomplicated urinary tract infections in young women, is resistant to amoxicillin because of 13-1ac -tamases and is resistant to erythromycin because of the presence of an enzyme that methylates an adenine in the 16S component of the 23S ribosomal RNA (rRNA). Coagulase-negative staphylococci are felt to be a reservoir of resistance genes amplified through antibiotic selection that occurs when antibiotics administered to patients achieve low concentrations in skin. The resistance genes can be transferred to S. aureus, making it resistant to multiple agents.
S t r e p t o c o c c u s p n e u m o n i a e
In 1941, 10,000 units of penicillin administered four times a day for 4 days cured patients of pneumococcal pneumonia. Today, a patient could receive 24 million units of penicillin a day and die of pneumococcal meningitis. Pneumococci remain the most important cause of community-acquired pneumonia and a major cause of otitis media, sinusitis, and meningitis both in children and adults. (26) (27) (28) Strains with the highest level of resistance show reduction in the affinity of the five high molecular weight PBPs, la, lb, 2a, 2x, and 2b. The PBP 2b and 2x genes of penicillin-resistant pneumococci differ extensively from the genes of susceptible pneumococci. It appears that the altered PBP genes arose by interspecies recombinational events in which segments of the PBP structural genes had been replaced by re- (31) .
High-level resistance of pneumococci has been encountered in Hungary, where in the period of 19.8.8 to 1989, 58% ofS. pneumoniae were resistant to penicillin, and 70% of children who were colonized with S. pneunmniae carried resistant strains that were also resistant to tetracycline, erythromycin, trimethoprim/sulfamethoxazole (TMP/SMX), and 30% resistant to chloramphenicol (32) .
In addition, resistant pneumococcal strains have emerged independently in many parts of the world.
The resistance of pneumococci to macrolides such as erythromycin averages 20 to 7 : 25% in France, 18 to 20% in Japan, and less than 10% in Spain (33) . This resistance, referred to as macrolide-lincinoidstreptogramin (MLS) resistance, is a result of a plasmid-mediated production of an enzyme that methylates a crucial adenine residue in 23S rRNA. This results in the failure of binding of the erythromycin and related macrolides. The resistance can be induced by erythromycin, or bacteria can produce the methylase continuously, which is constitutive resistance. Macrolide-resistant S. pneumoniae are found in France, Belgium, and the United Kingdom, but are uncommon so far in the United States (33) .
The extensive use of macrolides in France compared to a lower use in Spain is thought to explain the difference in resistance between the two countries. It is possible that increased use of the new macrolides azithromycin, clarithromycin, and roxitkromycin will cause an increase in macrolide-resistant S. pneumoniae in the United States. Erythromycin has been less frequently administered to adults in the United States because it causes gastrointestinal upset, but the new agents are better tolerated, and interest in using these agents to treat respiratory infections will increase resistance.
Streptococcus pyogenes
Streptococcus pyogenes, the group A streptococcus, has remained susceptible to penicillin, although the concentrations required to kill this organism have been increasing over the past two decades. MLS resistance was a problem in Japan in the early 1960s and has been a problem for years in France where there has been extensive use of erythromycin, josamycin, another oral macrolide, and pristinamycin, a closely related compound (33, 34) . Outbreaks of erythromycin-resistant group A streptococci have occurred in day-care centers in
Sweden (35) . In western Australia, only 1% of S. pyogenes were resistant in 1985, but 17.6% were resistant in 1987 (36) .
The use of oral erythromycin in Finland tripled from 1979 to 1989, and the ffequen- 
cy of erythromycin resistance of group A streptococci from throat swabs increased from 7 to 20% and in cutaneous lesions increased from 11 to 31% in 1990 (37) . Resistance was of muhiclonal origin, which indicates that it appeared simultaneously in many areas and was not a result of one strain spreading across Finland. This resistance was associated with the failure of thera/3y for pharyngitis and skin infection, which indicates that the resistance was of clinical significance and not just a laboratory phenomenon. Macrolide-resistance of group A streptococci may become a serious problem. Sepsis and shock now occur as a result of infection with a particularly virulent new group A streptococci (38) , and the increased use of new macrolide antibiotics clarithromycin, azithromycin, and roxithromycin will increase the likelihood that resistance will increase (39) .
Enterococci
There currently are 12 enterococcal species, but Enterococcus faecalis accounts for 90% and E. faecium for 5% of cases around the world of endocarditis and urinary tract, wound, intra-abdominal, and pelvic infections. Enterococci have become the third most commonly encountered, hospital-acquired organism in the United States (23, 40) . Since 1983, penicillinase-producing E. faecalis have been found in many parts of the United States and Europe, and localized outbreaks have occurred (23, 40, 41) . Its 13-1actamase is similar to the 13-1actamase of staphylococci. Aminoglycosides are used with penicillin, ampicillin, or vancomycin to treat serious enterococcal infections to achieve synergistic bactericidal activity; penicillin, ampicillin, and vancomycin by themselves are not bactericidal for enterococci. In Wisconsin in 1987, 35% of enterococci showed high-level gentamicin resistance (MIC > 2000 ixg/ml). Nationwide, 25% of enterococci possess high-level aminoglycoside-inactivating enzymes that cause resistance, and in other countries the percent of resistant isolates is higher (23, 
40-42).
Glycopeptides such as vancomycin and teicoplanin inhibit late stages in bacterial cell wall peptidoglycan synthesis (1) . Vancomycin-and teicoplanin-resistant enterococci are found in Europe and the United States (43, 44) . There are three major phenotypes of vancomycin resistance (44, 45) ( Table 3) . High-level resistance to glycopeptides is mediated by a 34-kb plasmid and is transferable from E. faecium by conjugation to different Gram-positive bacteria such as oral streptococci, group A streptococci, and Listeria monocytogenes (44, 45) . 47). The [3-1actamase is called TEM after a Greek girl from whom an E. coli strain was isolated that produced a plasmid-mediated 13-1actamase (Fig. 3) Moraxella (Branhamella) catarrhalis causes otitis med~ and bacterial bronchitis in elderly individuals with chronic lung disease. In the 1970s, virtually 100% of isolates were susceptible to ampicillin, but now in excess of 75% produce 13-1actamases that inactivate ampicillin, amoxicillin, and cefaclor, oral antibiotics widely used to treat ear and sinus infections (49) .
Penicillin was the drug of choice to treat gonorrhea, but over the years the concentration of penicillin needed to achieve cure rose as a result of a chromosomal mutation that reduced the affinity of PBPs for penicillin. In 1976, the plasmid-mediated TEM terococci. In addition, resistance to ciprofloxacin, a fluoroquinolone, is the result of an altered DNA gyrase A subunit (18) . pathogen. This is particularly a problem in developing countries.
Hospital Bacteria
In the mid-1980s in France and Germany, the failure of therapy for Klebsiella infections suddenly occurred because Klebsiella pneumoniae were resistant to cefotaxime, ceftriaxone, or ceftazidime, agents considered totally [3-1actamase-stable. Resistance was a result of new ~-lactamases initially referred to by the compound that they preferentially destroyed, such as CTX-I for cefotaxime or CAZ-I for ceftazidime (7, 8) (Fig. 3) . As already noted, these ~-lactamases differ from the original TEM-I enzyme by one, two, or three amino acids, and have been designated as There are also amino acid variants of another 18-1actam-ase, SHV-1 (sulfohydrovariable inhibited).
There are now eight SHV enzymes (7, 8 Klebsiella. These organisms, particularly E. cloacae, possess a cephalosporinase referred to as a type 1 enzyme (7, 8, 56) . The 13-1actamases are of chromosomal origin and not normally expressed, but expression of high concentrations of the enzyme is triggered by exposure to certain cephalosporins (56) . Most resistance of Enterobacter to isi3-1actams is a result of selection of preexisting mutant organisms that produce large amounts of ~3-1actamase constitutively. Some of these organisms also have decreased expression of the outer membrane protein porin F, the channel through which cephalosporins cross the outer cell wall of a Gram-negative bacterium, coupled with increased expression of porin C, a channel through which the cephalosporins do not readily pass. This results in inhibition of the entry of the cephalosporins or of penicillins. High affinity of the 13-1actamase for the cephalosporins with a decreased amount of drug coming into the periplasmic space where the 13-1actamase resides results in destruction of the cephalosporin (Fig. 5) . The [3-1actamase inhibitors clavulanate, sulbactam, and tazobactam do not inhibit the type 1 [3-1actamases found in Enterobacrer (7, 8) . Extensive use of iB-lactamasestable cephalosporins, particularly in intensive care units in hospitals, acts as a selection pressure to cause the appearance of Enterobacter, and numerous serious infections have occurred, including lethal bacteremias (55) .
The carbapenem imipenem inhibits Enterobacter species because it enters the periplasmic space and reaches the PBPs via a different porin channel than that used by cephalosporins, and it is very ~-lactamasestable, lmipenem is a very effective inducer of the production of type 1 i3-1actamase. Clinical isolates recently have been found that are resistant to imipenem. They lack the major outer membrane porins and have increased [B-lactamase production in the periplasmic space with destruction of imipenem (57) . I would anticipate that by the end of the decade, we will see increasing numbers of imipenem-resistant Enterobacter.
Cephalosporin resistance can also occur with Proteus and Serratia species, albeit so far a less frequent problem. Serratia nmrcescens have become increasingly common as a cause of nosocomial wound, urinary tract, pulmonary, and even bacteremic infections. In general, S. m~rcescens in the United States are susceptible to fluoroquinolones (MlCs < 1 ~g/ml). Extensive resistance of Serratia to the fluoroquinoiones has been found in Japan (•8), and we have similar organisms in our hospital. The mechanism of the resistance is a mutation that results in an amino acid change at a critical turn in the A subunit of the DNA gyrase.
Outbreaks of infection that are a result of aminoglycoside-resistant S. marcescens have occurred. These isolates possess enzymes that adenylate, phosphorylate, or acetylate the aminoglycosides (Fig, 4) . This causes the aminoglycoside to bind less well to its receptor protein and also results in the failure to produce a protein that causes rapid uptake of aminoglycosides, as occurs (plasmld or death bacteria via outer merechromosomal) brane proteins, porins. In { the space between the =-=,y'Sl-°"w'-*"/~'lactamase-" destroyed/l-lactam ' survivesCell outer wall and the cytoplasmic membrane, 13-1aclamases can deslroy the 6-1actams before they reach and bind to PBPs.
in susceptible bacteria. The aminoglycoside-modifying enzymes exist in the periplasmic space of Gram-negative bacteria and are highly efficient at producing resistance. Serratia resistant to i3-1actams, aminoglycosides, fluoroquinolones, and even TMP/SMX have been found in hospitals in the United States, Europe, and Japan.
Pseuclonumas aeruginosa is a major cause of serious infection in many patients, particularly those who lack white cells as a result of hematologic malignancy or chemotherapy (58) . Resistance usually is a combination of poor entry of antibiotics and the presence of enzymes that inactivate or modify the antibiotics (7) (8) (9) . All P. aerug~osa contain an inducible, chromosomally mediated cephalosporinase (7, 8) . Some otherwise [3-1actam- ase-stable cephalosporins induce the production of large amounts of the 13-1actamase, which results in their own destruction. The resistance of Pseuckmumas to antipseudomonas penicillins is usually a result of the presence of the plasmid-mediated TEM-I IB-lactamase. Other plasmid-mediated 13-1actamases will hydrolyze antipseudomonas penicillins and cefoperazone and cefsulodin, two antipseudomonas cephalosporins; these lB-lactamases are abbreviated PSE for Pseudomonas and are numbered 1 to 4-Cefiazidime and aztreonam, a monobactam, are not hydrolyzed by these [3- 1actamases, but ceftazidime can cause selection of hyperproducers of [B-lactamase that render the organism resistant to it and to aztreonam (59) . Aminoglycoside-inactivating enzymes are common in Pseudomonas, and a 6'-N-acyl-transferase enzyme occurs on a transposon in Pseudomonas and mediates resistance to the most stable aminoglycoside, amikacin (2) . Clinical isolates ofP. aeruginosa that are resistant to all aminoglycosides because of altered cell wall lipopolysaccharide and porins cause the lack of accumulation of drugs and are an extremely common cause of respiratory infection in patients with cystic fibrosis or in burn patients.
The resistance of P. aeruginosa to the carbapenem, imipenem, has increased (59) . A recent study from the Centers for Disease Control revealed that resistance to imipenem isolated from the respiratory tract of patients in intensive care units and in teaching hospitals had increased by 25% in the period from 1986 through 1990 (59) . Similar resistance has been noted in Japan.
The resistant P. aeruginosa lack a D2 outer membrane protein. Two new carbapenems, meropenem and a drug under early clinical investigation, LJC 10,627, are less effective inducers of the [3-1actamase. They inhibit some imipenem-resistant P. aeruginosa, but P. aeruginosa that produce large amounts of IB-lactamase and that have lost the D2 outer membrane protein are highly resistant to all the carbapenems because inadequate numbers of molecules reach the PBPs.
In 1984, virtually 100% of P. aeruginosa in the United States, Europe, and Japan were inhibited by < 1 ~g/ml ofciprofloxacin (18) . Today in some institutions, 25% of P.
aemginosa are resistant to all the fluoroquinolones (18) . This has been particularly true in isolates from individuals with respiratory infection with cystic fibrosis or severe wound infections. Resistance in these strains has been shown to be a result of a combination of alteration of the A subunit of the DNA g~/rase and changes in outer membrane proteins as well as changes in cell wall lipopolysaccharide (58, 60) .
Pseudomonas cepacia, an important nosocomial pathogen and a cause of lung abscesses in cystic fibrosis patients, is resistant to 13-1actams, fluoroquinolones, and aminoglycosides (58) . P. pseudomallei, a major pathogen in the Far East, is resistant to SCIENCE * VOL. 257 * 21 AUGUST 1992 many aminoglycosides and many other agents and has developed new ~-lactamases, which make it resistant to the broadspectrum cephalosporins and even to 13-1ac-tamase inhibitors.
Xanthomonas maltophilia, formerly called Pseudomonas maltophilia, produces two inducible 18-1actamases, one of which is a zinc metallo enzyme that destroys all ~-lactam compounds (Fig. 3) . Xanthomonas is resistant to virtually all antibiotics, including the new fluoroquinolones and aminoglycosides (61) . Xanthomonas has caused outbreaks in intensive care units in which there has been extensive use of imipenem (61) .
Acinetobacter calcoaceticus anitratus has
become an important cause of nosocomial infections in the hospital (58) . It is resistant to [8-1actams, aminoglycosides, tetracy- clines, and aminoglycosides. Most Acinembacter have been susceptible to carbapenems such as imipenem, but Acinetobacter probably will become resistant to these agents as have many other organisms.
Anaerobic Bacteria
Twenty years ago, all anaerobic bacteria in the mouth that were capable of causing aspiration pneumonia were susceptible to penicillin G. This is no longer the case.
Bacteroides melaninogenicus and other oral
Bacteroides make ~-lactamases that destroy penicillins (62) (Fig. 3) . Resistance of B.
flagilis, the major anaerobic organism in the large bowel, to ~-lactams ranges from 3 to 30%, depending upon whether it is in the United States, Canada, or Europe. Some B.
thetaiotaomicron hydrolyze highly [3-1actam. ase-stable compounds such as the cephalosporin cefoxitin and even imipenem (7, 8, 62) . Because genetic material can be exchanged between Bacteroides and E. coli and vice versa, it is conceivable that within this decade we will see Enterobacteriaceae resistant to carbapenems such as imipenem and meropenem.
Before 1970, less than 30% of Bacteroides that caused intra-abdominal or gynecological infection were resistant to tetracycline. Now, it is rare to find a susceptible strain because most organisms possess a plasmid-mediated protein that causes efflux of tetracyclines. Resistance to metronidazole, a nitroimidazole, has been exceedingly rare, but plasmid resistance to metronidazole in Clostridium species has been noted.
Summary
Antibiotic use has contributed significantly to the increased resistance found in many Enterobacteriaceae, particularly the new [3-1actamases found in Klebsiella species, and to the appearance of Enterobacter and Pseudomonas that produce large amounts of 18-1actamase (63) aeruginosa to carbapenems and the appearance of Xanthomonas resistant to carbapeneros in intensive care units.
Mechanisms to overcome bacterial resistance range from obvious hygienic practices to stop the spread of bacteria in a hospital to the synthesis of agents with improved antimicrobial activity (58) . Antibiotic control programs have proved to be an effective way to reduce inappropriate use of antibiotics in hospitals. Such programs are sorely needed in the community, particularly in residence facilities for the elderly.
The need for new antibiotics will continue because bacteria have a remarkable ability to overcome each new agent synthesized. Appropriate use of antibiotics will delay and in many cases prevent the emergence of the resistance discussed herein. The responsibility of reducing resistance lies with the physician who uses antimicrobial agents and with patients who demand antibiotics when the illness is viral and when antibiotics are not indicated. It also is critical for the pharmaceutical industry not to promote inappropriate use of antibiotics for humans or for animals because this selective pressure has been what has brought us to this crisis.
The Origin of Plagues:
Old and New
Richard M. Krause
Viruses and bacteria e m e r g e in n e w and old forms to cause disease epidemics. S o m e mic r o o r g a n i s m s recur w h e n changing life-styles (including increased international travel) offer new opportunities; others arise from n e w genetic variations. T h e s e various e p i d e m i c s c o n n e c t the future with the past, offering lessons for guarding the health of g e n e r a t Acquired immunodeficiency syndrome is the most contemporary example of~human vulnerability to the microbial world, and there is genuine concern that another "new" microbe, or a genetic variation of an old one, can and will "go global" as AIDS has done. A new epidemic may be incubating even now in the crowded, unsanitary mega-cities of the developing world, or in remote jungles in Africa, South America, or Asia--once sparsely inhabited regions that have recently been altered by modern
civilization (I-4).
AIDS is not the only case of a microbial threat to human beings in the late 20th century. Since the 1970s, a series of unanticipated outbreaks of microbial diseases startled inhabitants of the United States. Legionnaires' disease, toxic shock syndrome, and Lyme disease all happened before the recognition of AIDS in 1981.
In addition to these threats within the United States, strange epidemics have been occurring elsewhere in the world. In Africa, outbreaks of the deadly Ebola virus took the lives of 50% of the people who became infected. A majority of the doctors and nurses who treated these patients also died of the disease. After fatal but localized outbreaks of Ebola fever, the disease failed to become a worldwide epidemic. At the same time, however, the AIDS virus, human immunodeficiency virus (HIV), was spreading from the rural communities of Africa to the towns and cities, infecting thousands of people in Central Africa alone. After a few years, HIV, which has a long latency period, manifested itself when those who were infected developed the medical symptoms of full-blown disease. By that time, AIDS had spread from Africa to the United States, Europe, Asia, and elsewhere.
Many factors interact and contribute to the teemergence of old infectious diseases or
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the emergence of new ones. More often than not, epidemics occur because of changes in the patterns of human behavior, social organization, urbanization, and agriculture. However, the most important factor is the spread of microbial organisms from points of origin as a result of the migration and travel of their human hosts (5) .
In ancient times, infectious diseases spread slowly but steadily along caravan routes throughout the Roman and Asian world (6, 7) . From A.D. 165 to 180, measles was spread along the caravan routes, and from A.D. 251 to 266 smallpox was carried. One-third of the population died. Such a catastrophe did not recur until the bubonic plague spread from Asia to Europe in the 13th and 14th centuries. This occurred when the horsemen of the Mongol armies raced across the steppes of Asia, transmitting the disease from the point of origin in northern Burma. They carried fleas infected with plague bacillus. From there the plague moved farther eastward via the caravan routes to Europe and elsewhere. After 1492, the oceans became highways that further extended the dispersal of disease agents. It became possible for plagues such as smallpox and measles to circle the globe within a year. The oceans remained the predominant route of transmission until the present era of mass air travel. Today, airborne travelers incubating infections can reach any point on the globe within 24 hours. As a consequence, worldwide exposure to a highly infectious virus, such as influenza, occurs in a matter of weeks.
'However, microbes are not idle bystander~, waiting for new opportunities offered by human mobility, ignorance, or neglect. Microbes possess remarkable genetic versatility that enables them to develop new pathogenic vigor, to escape population immunity by acquiring new antigens, and to develop antibiotic resistance.
For these reasons, it is necessary to be prepared for new epidemics caused by old
